Trade

with

Targacept Inc
(NASDAQ: TRGT)
AdChoices
2.32
-0.02
-0.85%
After Hours :
2.33
+0.01
+0.43%

Open

2.34

Previous Close

2.34

Volume (Avg)

45.20k (194.51k)

Day's Range

2.25-2.35

52Wk Range

2.25-6.11

Market Cap.

79.08M

Dividend Rate ( Yield )

-

Beta

1.86

Shares Outstanding

33.79M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 3.63M

    • Net Income

    • -46.70M

    • Market Cap.

    • 79.08M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -22,871.76

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.86

    • Forward P/E

    • -

    • Price/Sales

    • 370.37

    • Price/Book Value

    • 0.68

    • Price/Cash flow

    • -1.77

      • EBITDA

      • -46.10M

      • Return on Capital %

      • -33.84

      • Return on Equity %

      • -35.90

      • Return on Assets %

      • -33.84

      • Book Value/Share

      • 3.46

      • Shares Outstanding

      • 33.79M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -97.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -28.98

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -21,268.06

            • 39.38

            • Net Profit Margin

            • -22,871.76

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 86.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -289.70

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -290.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 13.17

              • 2.92

              • Quick Ratio

              • 13.04

              • 2.35

              • Interest Coverage

              • -1,207.92

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 3.46

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.60

                • 243.90

                • P/E Ratio 5-Year High

                • -20.79

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.55

                • 124.82

                • Price/Sales Ratio

                • 370.37

                • 9.29

                • Price/Book Value

                • 0.68

                • 8.39

                • Price/Cash Flow Ratio

                • -1.77

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -35.90

                    (-17.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -33.84

                    (-9.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -35.59

                    (-17.20)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -47.22M
                  Operating Margin
                  -1,301.07
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.77
                  Ownership

                  Institutional Ownership

                  93.34%

                  Top 10 Institutions

                  75.41%

                  Mutual Fund Ownership

                  16.06%

                  Float

                  68.06%

                  5% / Insider Ownership

                  0.30%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    1,863,661

                  • 156.58

                  • 5.52

                  • Vanguard Total Stock Mkt Idx

                  •  

                    626,364

                  • 0.00

                  • 1.85

                  • Prudential Jennison Health Sciences

                  •  

                    548,417

                  • 0.00

                  • 1.62

                  • Vanguard Extended Market Index Fund

                  •  

                    389,184

                  • 2.28

                  • 1.15

                  • Fidelity® Small Cap Stock Fund

                  •  

                    316,533

                  • -27.97

                  • 0.94

                  • TFS Market Neutral Fund

                  •  

                    275,351

                  • -17.20

                  • 0.81

                  • Swedbank Robur Medica

                  •  

                    193,262

                  • -22.90

                  • 0.59

                  • Franklin Biotechnology Discovery Fund

                  •  

                    191,432

                  • -77.47

                  • 0.57

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    150,431

                  • 0.00

                  • 0.45

                  • Bridgeway Ultra Small Company Market

                  •  

                    103,900

                  • 0.00

                  • 0.31

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Bvf Inc

                  •  

                    6,655,128

                  • +7.83%

                  • 19.69

                  • NEA Management Company, LLC

                  •  

                    4,566,666

                  • 0.00%

                  • 13.51

                  • Franklin Advisers, Inc.

                  •  

                    2,713,347

                  • +14.77%

                  • 8.03

                  • Camber Capital Management LLC

                  •  

                    1,560,000

                  • 0.00%

                  • 4.62

                  • BlackRock Fund Advisors

                  •  

                    1,023,278

                  • -23.20%

                  • 3.03

                  • Vanguard Group, Inc.

                  •  

                    973,041

                  • -2.97%

                  • 2.88

                  • Technical Financial Services LLC

                  •  

                    740,745

                  • +149.50%

                  • 2.19

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Targacept, Inc., is a biopharmaceutical company engaged incorporated in the year 2001. The Company is engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disord...moreers of the central nervous system. The Company’s NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs, which are found on nerve cells throughout the nervous system and serves as key regulators of nervous system activity. The Company’s product candidates are TC-5214, TC-1734, TC-6499, AZD1446 or TC-6683, TC-5619 and TC-6987. It has multiple clinical-stage product candidates and preclinical programs in areas where there are significant medical needs and commercial potential, as well as proprietary drug discovery technologies. It also has a cognition-fo...morecused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. In July 2007, it entered into a product development and commercialization agreement with SmithKline Beecham Corporation, doing business as GlaxoSmithKline, and Glaxo Group Limited. The Company is conducting an ongoing Phase 2b clinical trial of TC-5214. The Company and AstraZeneca are conducting an ongoing exploratory Phase 2 trial of TC-1734 in adults with ADHD. TC-5619 is a novel small molecule that the company plans to develop for cognitive dysfunction in schizophrenia or potentially one or more other conditions characterized by cognitive impairment. TC-5619 modulates the activity of the a7 NNR. AZD1446 or TC-6683 is a novel small molecule that it discovered and advanced as part of the preclinical research collaboration that it is conducting with AstraZeneca. AZD1446 modulates the activity of the a4ß2 NNR and is in development for Alzheimer’s disease, ADHD or one or more other conditions characterized by cognitive impairment. The Company is subject to government regulations.lessless

                  Key People

                  Stephen A. Hill,B.M.

                  CEO/Director/President

                  John P. Richard

                  Chairman of the Board/Director

                  Alan A. Musso

                  Assistant Secretary/CFO/Senior VP, Divisional/Treasurer

                  Steven M. Toler

                  Vice President, Divisional

                  Mr. Charles Blixt

                  Director

                  • Targacept Inc

                  • 100 North Main Street

                  • Winston-Salem, NC 27101

                  • USA.Map

                  • Phone: +1 336 480-2100

                  • Fax: +1 336 480-2107

                  • targacept.com

                  Incorporated

                  1997

                  Employees

                  40

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: